Most Americans Think Our Morals Are Going To Hell
Ask anyone about the state of moral values in the U.S. and you’re likely to get a response along the lines of, “we’re going to hell.”
Most Americans — 72 percent — are convinced that moral values in the U.S. are decaying, according to a new Gallup poll, and most people believe the current state of moral values isn’t all that great to begin with. Nearly half of those polled, 45 percent, called the state of moral values in the U.S. “poor,” while 34 percent said they are “only fair.”
Just 19 percent rated American morals as either “excellent” or “good,” and only 22 percent say the state of moral values is getting better.
Unsurprisingly perhaps, social conservatives have consistently been most likely to tell pollsters that the nation’s moral values are deteriorating, but the latest Gallup findings showed an uptick from 2014 to 2015 among social moderates and social liberals who believe moral values are regressing.
Related: How U.S. Morals Stack Up Against the World
Gallup also found that Americans’ views of the moral acceptability of a number of key issues has been shifting to the left since 2001. The largest shift was on gay or lesbian relations, with a 23 percentage point increase in the share of people who say that behavior is morally acceptable. The change coincides with a sharp increase in support for same-sex marriage.
Sex between unmarried people has also become more acceptable, as has having babies outside of marriage. Polygamy and divorce are also now acceptable to a greater portion of the population than in 2001. On the other hand, the views of married men and women having an affair haven’t changed much, with just 8 percent of Americans saying it’s morally tolerable.
However, respondents to the poll about the current and future state of moral values weren’t necessarily responding with those charged social and political issues in mind. In many cases, Gallup suggests, their views of the moral direction of the country were rooted in something much more basic: “That is, their views have less to do with greater acceptance of same-sex marriage or having babies out of wedlock and other hot-button issues, and more to do with matters of basic civility and respect for each other,” Gallup’s Justin McCarthy wrote.
Clearly, the Golden Rule is still the bedrock of our moral code: Love thy neighbor as thyself.
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.